TKI Hikes Survival in Recurrent Ovarian Cancer

Cediranib, bevacizumab, and novel antiangiogenic agents continue to improve survival in first-line and recurrent ovarian cancer, as reported by Dr. Stanley Kaye from ECC 2013.
Source: Medscape ObGyn Podcast - Category: OBGYN Authors: Source Type: podcasts